Heptares-Powered Sosei's Incoming CEO Explains What Happens Next
Executive Summary
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.
You may also be interested in...
Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion
Japan-based Sosei's recent equity offering made its shareholder base more international and will help finance the evolution of the group's proprietary pipeline.
Sosei Names New CEO
Japanese biopharma Sosei Group Corporation has appointed Peter Bains representative executive officer and CEO, taking over from founder Shinichi Tamura, who has been appointed representative executive officer and executive chair. Bains joins the company from Syngene International Ltd., where he was executive director and CEO. Prior to this, he held leadership positions at several businesses, including Heptares Therapeutics Ltd and GlaxoSmithKline PLC. (Also see "Heptares-Powered Sosei's Incoming CEO Explains What Happens Next" - Scrip, 28 Apr, 2016.)
Kymab, Heptares Enter GPCR Targeting Pact
Two of Britain's leading science innovators – Mab specialist Kymab Ltd. and GPCR-targeting Heptares Therapeutics – are joining forces to discover, develop and commercialize new antibody drugs targeting a number of G protein-coupled receptors, focusing initially on immuno-oncology.